Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 20 de 69
Filter
1.
J Psychopharmacol ; 37(5): 437-448, 2023 05.
Article in English | MEDLINE | ID: covidwho-20233017

ABSTRACT

The opioid crisis' pathways from first exposure onwards to eventual illnesses and fatalities are multiple, intertwined and difficult to dissect. Here, we offer a multidisciplinary appraisal of the relationships among mental health, chronic pain, prescribing patterns worldwide and the opioid crisis. Because the opioid crisis' toll is especially harsh on young people, emphasis is given on data regarding the younger strata of the population. Because analgesic opioid prescription constitute a recognised entry point towards misuse, opioid use disorder, and ultimately overdose, prescribing patterns across different countries are examined as a modifiable hazard factor along these pathways of risk. Psychiatrists are called to play a more compelling role in this urgent conversation, as they are uniquely placed to provide synthesis and lead action among the different fields of knowledge and care that lie at the crossroads of the opioid crisis. Psychiatrists are also ideally positioned to gauge and disseminate the foundations for diagnosis and clinical management of mental conditions associated with chronic pain, including the identification of hazardous and protective factors. It is our hope to spark more interdisciplinary exchanges and encourage psychiatrists worldwide to become leaders in an urgent conversation with interlocutors from the clinical and basic sciences, policy makers and stakeholders including clients and their families.


Subject(s)
Chronic Pain , Opioid-Related Disorders , Humans , Adolescent , Chronic Pain/drug therapy , Mental Health , Opioid Epidemic , Analgesics, Opioid/adverse effects , Opioid-Related Disorders/drug therapy , Practice Patterns, Physicians'
2.
Int J Drug Policy ; 116: 104032, 2023 06.
Article in English | MEDLINE | ID: covidwho-2327290

ABSTRACT

Public transport disruptions caused by the COVID-19 pandemic had wide-ranging impacts on the ability of individuals to access health care. Individuals with opioid use disorder represent an especially vulnerable population due to the necessity of frequent, supervised doses of opioid agonists. Focused on Toronto, a major Canadian city suffering from the opioid epidemic, this analysis uses novel realistic routing methodologies to quantify how travel times to individuals\220 nearest clinics changed due to public transport disruptions from 2019 to 2020. Individuals seeking opioid agonist treatment face very constrained windows of access due to the need to manage work and other essential activities. We find that thousands of households in the most materially and socially deprived neighbourhoods crossed 30 and 20-minute travel time thresholds to their nearest clinic. As even small changes to travel times can lead to missed appointments and heighten the chances of overdose and death, understanding the distribution of those most impacted can help inform future policy measures to ensure adequate access to care.


Subject(s)
COVID-19 , Drug Overdose , Opioid-Related Disorders , Humans , Analgesics, Opioid/therapeutic use , COVID-19/epidemiology , Opioid Epidemic , Pandemics , Canada , COVID-19 Drug Treatment , Opioid-Related Disorders/epidemiology , Opioid-Related Disorders/drug therapy , Drug Overdose/epidemiology , Drug Overdose/drug therapy
3.
Anaesthesiol Intensive Ther ; 54(3): 271-278, 2022.
Article in English | MEDLINE | ID: covidwho-2308091

ABSTRACT

The current opioid epidemic has had a massive impact on the critical care sector. This is due to an increase in the number of acute opioid overdose-related admissions and the number of opioid-dependent and opioid-tolerant patients admitted to intensive care units (ICUs). This review discusses the challenges that intensive care physicians face when caring for patients suffering from opioid-related disorders and analyses existing solutions. Preference for non-opioid analgesics, treatment of acute pain in the ICUs to avoid chronic pain syndrome, and education of patients and caregivers are critical to preventing this pandemic.


Subject(s)
Analgesics, Non-Narcotic , Drug Overdose , Opioid-Related Disorders , Analgesics, Opioid/adverse effects , Critical Care , Drug Overdose/drug therapy , Drug Overdose/epidemiology , Humans , Intensive Care Units , Opioid Epidemic , Opioid-Related Disorders/epidemiology , Opioid-Related Disorders/prevention & control
4.
Int J Environ Res Public Health ; 20(7)2023 03 28.
Article in English | MEDLINE | ID: covidwho-2305821

ABSTRACT

The opioid epidemic has continued to be an ongoing public health crisis within Metro Atlanta for the last three decades. However, estimating opioid use and exposure in a large population is almost impossible, and alternative methods are being explored, including wastewater-based epidemiology. Wastewater contains various contaminants that can be monitored to track pathogens, infectious diseases, viruses, opioids, and more. This commentary is focusing on two issues: use of opioid residue data in wastewater as an alternative method for opioid exposure assessment in the community, and the adoption of a streamlined approach that can be utilized by public health officials. Opioid metabolites travel through the sanitary sewer through urine, fecal matter, and improper disposal of opioids to local wastewater treatment plants. Public health officials and researchers within various entities have utilized numerous approaches to reduce the impacts associated with opioid use. National wastewater monitoring programs and wastewater-based epidemiology are approaches that have been utilized globally by researchers and public health officials to combat the opioid epidemic. Currently, public health officials and policy makers within Metro Atlanta are exploring different solutions to reduce opioid use and opioid-related deaths throughout the community. In this commentary, we are proposing a new innovative approach for monitoring opioid use and analyzing trends by utilizing wastewater-based epidemiologic methods, which may help public health officials worldwide manage the opioid epidemic in a large metro area in the future.


Subject(s)
Analgesics, Opioid , Opioid-Related Disorders , Humans , Analgesics, Opioid/therapeutic use , Georgia/epidemiology , Wastewater , Opioid Epidemic , Opioid-Related Disorders/epidemiology , Opioid-Related Disorders/drug therapy
5.
Crit Rev Clin Lab Sci ; 59(5): 309-331, 2022 08.
Article in English | MEDLINE | ID: covidwho-2256802

ABSTRACT

Since 1999, the opioid epidemic in North America has resulted in over 1 million deaths, and it continues to escalate despite numerous efforts in various arenas to combat the upward trend. Clinical laboratories provide drug testing to support practices such as emergency medicine, substance use disorder treatment, and pain management; increasingly, these laboratories are collaborating in novel partnerships including drug-checking services (DCS) and multidisciplinary treatment teams. This review examines drug testing related to management of licit and illicit opioid use, new technologies and test strategies employed by clinical laboratories, barriers hindering laboratory response to the opioid epidemic, and areas for improvement and standardization within drug testing. Literature search terms included combinations of "opioid," "opiate," "fentanyl," "laboratory," "epidemic," "crisis," "mass spectrometry," "immunoassay," "drug screen," "drug test," "guidelines," plus review of PubMed "similar articles" and references within publications. While immunoassay (IA) and point-of-care (POC) test options for synthetic opioids are increasingly available, mass spectrometry (MS) platforms offer the greatest flexibility and sensitivity for detecting novel, potent opioids. Previously reserved as a second-tier application in most drug test algorithms, MS assays are gaining a larger role in initial screening for specific patients and DCS. However, there are substantial differences among laboratories in terms of updating test menus, algorithms, and technologies to meet changing clinical needs. While some clinical laboratories lack the resources and expertise to implement MS, many are also slow to adopt available IA and POC tests for newer opioids such as fentanyl. MS-based testing also presents challenges, including gaps in available guidance for assay validation and ongoing performance assessment that contribute to a dramatic lack of standardization among laboratories. We identify opportunities for improvement in laboratory operations, reporting, and interpretation of drug test results, including laboratorian and provider education and laboratory-focused guidelines. We also highlight the need for collaboration with providers, assay and instrument manufacturers, and national organizations to increase the effectiveness of clinical laboratory and provider efforts in preventing morbidity and mortality associated with opioid use and misuse.


Subject(s)
Analgesics, Opioid , Opioid-Related Disorders , Analgesics, Opioid/analysis , Fentanyl/analysis , Humans , Laboratories, Clinical , Opioid Epidemic , Opioid-Related Disorders/diagnosis , Opioid-Related Disorders/epidemiology
6.
Sr Care Pharm ; 38(2): 47-49, 2023 Feb 01.
Article in English | MEDLINE | ID: covidwho-2236883

ABSTRACT

Pharmacy-based Opioid Use Disorder (OUD) treatment has been identified as a central pillar in curbing the spiraling opioid epidemic that claimed more than 100,000 lives in the United States in a one year period for the first time. This epidemic is also partially responsible for the plummeting US life expectancy that began prior to the COVID-19 pandemic and has now claimed more than 500,000 lives since 1999 with more than 70% of the 70,630 overdose deaths in 2019 involved with an opioid. Older people are at increased risk of both OUD and OUD-related complications. Recent studies have demonstrated that people older than 65 years of age were more likely to die of OUD-related complications, and - because of an increased likelihood of polypharmacy - are more likely to experience a drug interaction that magnifies the risk of an opioid-related misadventure.


Subject(s)
COVID-19 , Opioid-Related Disorders , Humans , United States , Aged , Analgesics, Opioid/adverse effects , Opioid-Related Disorders/drug therapy , Opioid Epidemic , Pharmacists , Pandemics , COVID-19/epidemiology
7.
Int J Environ Res Public Health ; 19(22)2022 Nov 16.
Article in English | MEDLINE | ID: covidwho-2116016

ABSTRACT

The devastating impact of the opioid crisis on children and families in West Virginia was compounded by the COVID-19 pandemic and brought to light the critical need for greater mental health services and providers in the state. Parent-Child Interaction Therapy (PCIT) is an evidence-based treatment for child externalizing symptoms that teaches parents positive and appropriate strategies to manage child behaviors. The current qualitative study details barriers and facilitators to disseminating and implementing PCIT with opioid-impacted families across West Virginia during the COVID-19 pandemic. Therapists (n = 34) who participated in PCIT training and consultation through a State Opioid Response grant were asked to provide data about their experiences with PCIT training, consultation, and implementation. Almost all therapists (91%) reported barriers to telehealth PCIT (e.g., poor internet connection, unpredictability of sessions). Nearly half of therapists' cases (45%) were impacted directly by parental substance use. Qualitative findings about the impact of telehealth and opioid use on PCIT implementation are presented. The dissemination and implementation of PCIT in a state greatly impacted by poor telehealth capacity and the opioid epidemic differed from the implementation of PCIT training and treatment delivery in other states, highlighting the critical importance of exploring implementation factors in rural settings.


Subject(s)
COVID-19 , Humans , COVID-19/epidemiology , Analgesics, Opioid/therapeutic use , Opioid Epidemic , West Virginia/epidemiology , Pandemics , Parent-Child Relations
8.
J Am Acad Orthop Surg ; 30(20): e1302-e1310, 2022 10 15.
Article in English | MEDLINE | ID: covidwho-1988320

ABSTRACT

There is still an ongoing epidemic of opioid abuse in the United States. It has resulted in a major healthcare crisis and led to an alarming number of daily overdose deaths. Strong interventions from the medical community and the government had made progress toward control. Tragically, the COVID-19 pandemic made the death rate dramatically worse. The purpose of this article is to reexamine the origins of this situation and provide updates from the pandemic period. The authors review the medical-legal risks physicians face when prescribing pain-relieving medications for their orthopaedic patients. Methods for providing responsible pain management plans for patients are suggested.


Subject(s)
COVID-19 , Opioid-Related Disorders , Analgesics, Opioid/adverse effects , Humans , Opioid Epidemic , Opioid-Related Disorders/epidemiology , Pandemics , United States/epidemiology
12.
JAAPA ; 34(6): 1-4, 2021 Jun 01.
Article in English | MEDLINE | ID: covidwho-1684812

ABSTRACT

ABSTRACT: Preliminary data suggest that opioid-related overdose deaths have increased subsequent to COVID-19. Despite national support for expanding the role of physician assistants (PAs) and NPs in serving patients with opioid use disorder, these clinicians are held to complex and stringent regulatory barriers. COVID-19 triggered significant changes from regulatory and federal agencies, yet disparate policies and regulations persist between physicians and PAs and NPs. The dual epidemics of COVID-19 and opioid use disorder highlight the inadequate infrastructure required to support patients, communities, and clinicians, and may serve as the catalyst for eliminating barriers to care.


Subject(s)
COVID-19/epidemiology , Health Services Accessibility/legislation & jurisprudence , Opioid-Related Disorders/drug therapy , Opioid-Related Disorders/epidemiology , Buprenorphine/therapeutic use , COVID-19/prevention & control , Drug Prescriptions , Health Policy/legislation & jurisprudence , Humans , Legislation, Drug , Narcotic Antagonists/therapeutic use , Nurse Practitioners/legislation & jurisprudence , Opioid Epidemic , Physician Assistants/legislation & jurisprudence , Physicians/legislation & jurisprudence , SARS-CoV-2 , Telemedicine , United States/epidemiology
14.
Curr Opin Psychiatry ; 34(4): 344-350, 2021 07 01.
Article in English | MEDLINE | ID: covidwho-1631191

ABSTRACT

PURPOSE OF REVIEW: This review provides an update on recently published literature on the rise of illicit fentanyls, risks for overdose, combinations with other substances, e.g. stimulants, consequences, and treatment. RECENT FINDINGS: Overdose due to illicit synthetic opioids (e.g. fentanyl and fentanyl analogs) continues to rise in the US both preceding and during the COVID-19 pandemic. Fentanyl-related overdose is rising in new geographic areas e.g. the western USA. Stimulant-related overdose is also increasing nationwide driven by methamphetamine and cocaine. Polysubstance use, e.g. the use of a stimulant along with an opioid is driving stimulant-related overdose. Other medical consequences of injection drug use are rising including HIV and hepatitis C infections. Medication approaches to treating opioid use disorder remain the standard of care and there are new promising pharmacological approaches to treating methamphetamine use disorder. SUMMARY: A 'fourth wave' of high mortality involving methamphetamine and cocaine use has been gathering force in the USA. Availability and use of illicit fentanyls are still the major drivers of overdose deaths and the current rise in stimulant-related deaths appears entwined with the ongoing opioid epidemic.


Subject(s)
Analgesics, Opioid/poisoning , Central Nervous System Stimulants/poisoning , Cocaine-Related Disorders/epidemiology , Fentanyl/poisoning , Opiate Overdose/epidemiology , Opioid Epidemic/statistics & numerical data , Cocaine/poisoning , Comorbidity , Drug Overdose/epidemiology , Humans , Illicit Drugs/poisoning , Methamphetamine/poisoning
18.
Med Sci (Paris) ; 37(11): 1035-1041, 2021 Nov.
Article in French | MEDLINE | ID: covidwho-1545678

ABSTRACT

In order to effectively contribute to scientific knowledge, biomedical observations have to be validated and debated by scientists in the relevant field. Along this debate that mainly takes place in the scientific literature, citation of previous studies plays a major role. However, only a few academic studies have quantitatively evaluated the suitability and accuracy of scientific citations. Here we review these academic studies. Two types of misuse have been pointed out: Citation bias and citation distortion. First, scientific citations favor positive results and those supporting authors' conclusion. Second, many statements linked to a reference actually misrepresent the referenced findings. About 10% of all citations in biomedicine are strongly inaccurate and misleading for the reader. Finally, we give two examples illustrating how some citation misuses do affect public health: The opioid crisis in the USA and the unjustified fostering of hydroxychloroquine for Covid-19 treatment in France.


TITLE: Le mésusage des citations et ses conséquences en médecine. ABSTRACT: Les observations biomédicales ne deviennent une source de connaissance qu'après un débat entre chercheurs. Au cours de ce débat, la citation des études antérieures tient un rôle majeur, mais les travaux académiques qui en évaluent l'usage sont rares. Ils ont cependant pu révéler deux types de problèmes : les biais de citation et les écarts de sens entre l'étude antérieure citée et ce qu'en dit l'article citant. Dans cette revue, nous synthétisons ces travaux et en dégageons les principales caractéristiques : les études favorables à la conclusion des auteurs citants sont plus souvent citées que celles qui les questionnent ; des écarts de sens majeurs affectent environ 10 % des citations. Nous illustrons par deux exemples les conséquences de ce mésusage des citations.


Subject(s)
Public Health , Publication Bias , Publications , Disinformation , Humans , Opioid Epidemic , COVID-19 Drug Treatment
19.
World J Biol Psychiatry ; 23(6): 411-423, 2022 07.
Article in English | MEDLINE | ID: covidwho-1545827

ABSTRACT

Pharmacogenetic investigations into the opioid crisis suggest genetic variation could be a significant cause of opioid-related morbidity and mortality. Variability in opioid system genes, including single nucleotide polymorphisms, manifest after pharmacogenetic testing, as previously invisible risk factors for addiction and overdose. Pharmacodynamic genes regulate opioid-sensitive brain networks and neural reward circuitry. Pharmacokinetic genes expressed in drug metabolic pathways regulate blood levels of active vs. inactive opioid metabolites. Elucidating the complex interplay of genetic variations in pharmacokinetic and pharmacodynamic pathways will shed new light on the addictive and toxic properties of opioids. This narrative review serves to promote understanding of key genetic mechanisms affecting the metabolism and actions of opioids, and to explore causes of the recent surge in opioid-related mortality associated with COVID-19. Personalised treatment plans centred around an individual's genetic makeup could make opioid-based pain management and opioid use disorder (OUD) treatments safer and more effective at both the individual and system levels.


Subject(s)
COVID-19 , Opioid-Related Disorders , Humans , Opioid Epidemic , Analgesics, Opioid/adverse effects , Pharmacogenetics , Pain , Opioid-Related Disorders/drug therapy , Opioid-Related Disorders/genetics , Opioid-Related Disorders/epidemiology
SELECTION OF CITATIONS
SEARCH DETAIL